For the subpopulation with leukemia, the baseline use of recombinant thrombomodulin in 2010 was already high at 21.5% (95% CI 20.0%-23.1%) and further increased to 47.3% (95% CI 45.7%-48.9%) in 2017. This evidence concerns the gene THBD and leukemia.